AbbVie’s Boey wins CHMP backing in Europe

Version 1

Allergan Aesthetics, an AbbVie company, said the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has issued a positive opinion recommending approval of Boey (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults when those lines have an important psychological impact. AbbVie said the opinion covers the centralized EU procedure across 30 EU and EEA markets, with a European Commission decision expected in the coming months. The company says Boey could become the first botulinum neurotoxin serotype E approved in Europe for this use, with phase 3 data showing onset as early as eight hours and a shorter two- to three-week duration of effect. (news.abbvie.com)

Why it matters: This is a human aesthetics story, not an animal health one, but it still matters to veterinary professionals who track large diversified manufacturers, injectable biologics, and regulatory signals across the broader life sciences market. For AbbVie, Boey would add a fast-acting, short-duration option to its aesthetics portfolio at a time when the company is positioning the product as a differentiated “trial” neurotoxin for patients considering facial injectables. That matters because AbbVie’s broader aesthetics business has been under pressure, and because the same product recently hit a manufacturing-related complete response letter from the FDA in the U.S., underscoring how regional regulatory outcomes can diverge even when clinical data appear supportive. (fiercepharma.com)

What to watch: The next milestone is the European Commission’s final decision, plus any details on launch timing, clinician training, and whether AbbVie resolves the U.S. manufacturing questions without new clinical requirements. (news.abbvie.com)